Personal CFO Solutions LLC Purchases 210 Shares of AstraZeneca PLC (NASDAQ:AZN)

Personal CFO Solutions LLC boosted its position in AstraZeneca PLC (NASDAQ:AZN) by 1.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 21,298 shares of the company’s stock after purchasing an additional 210 shares during the quarter. Personal CFO Solutions LLC’s holdings in AstraZeneca were worth $1,395,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. FMR LLC lifted its position in shares of AstraZeneca by 1.1% during the 3rd quarter. FMR LLC now owns 23,117,447 shares of the company’s stock valued at $1,801,080,000 after acquiring an additional 258,477 shares during the period. Franklin Resources Inc. lifted its position in shares of AstraZeneca by 8.7% during the 3rd quarter. Franklin Resources Inc. now owns 19,122,675 shares of the company’s stock valued at $1,492,649,000 after acquiring an additional 1,522,715 shares during the period. Jennison Associates LLC lifted its position in shares of AstraZeneca by 3.1% during the 4th quarter. Jennison Associates LLC now owns 15,430,963 shares of the company’s stock valued at $1,011,037,000 after acquiring an additional 466,416 shares during the period. Fisher Asset Management LLC lifted its position in shares of AstraZeneca by 4.6% during the 4th quarter. Fisher Asset Management LLC now owns 10,959,852 shares of the company’s stock valued at $718,090,000 after acquiring an additional 479,692 shares during the period. Finally, Manning & Napier Advisors LLC lifted its position in shares of AstraZeneca by 17.7% during the 4th quarter. Manning & Napier Advisors LLC now owns 3,745,531 shares of the company’s stock valued at $245,407,000 after acquiring an additional 564,297 shares during the period. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Price Performance

Shares of AZN stock opened at $77.50 on Friday. The company has a quick ratio of 0.74, a current ratio of 0.93 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a twelve month low of $62.75 and a twelve month high of $87.68. The company has a market cap of $240.34 billion, a P/E ratio of 34.29, a P/E/G ratio of 1.42 and a beta of 0.41. The business has a fifty day simple moving average of $70.83 and a 200 day simple moving average of $72.74.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.05 earnings per share for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. On average, sell-side analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Monday, March 24th. Shareholders of record on Friday, February 21st will be issued a $1.03 dividend. This represents a yield of 2%. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from AstraZeneca’s previous semi-annual dividend of $0.49. AstraZeneca’s dividend payout ratio is presently 91.15%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. UBS Group upgraded AstraZeneca from a “neutral” rating to a “buy” rating in a research report on Thursday, February 13th. Morgan Stanley began coverage on AstraZeneca in a research report on Wednesday, February 12th. They set an “overweight” rating for the company. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.